Agammaglobulinemia Non-Bruton Type

Agammaglobulinemia, non-Bruton type (also called autosomal agammaglobulinemia) is a rare, inherited immune system condition where a child is born with a near-absence of mature B-cells, the cells that make antibodies. Because antibodies (immunoglobulins) are missing, the body cannot fight germs well, so serious ear, sinus, lung, and gut infections happen again and again, often starting after 6–9 months of age when a baby’s borrowed “maternal antibodies” fade. Unlike Bruton disease (BTK-related, X-linked), the “non-Bruton” forms are due to mutations in other genes needed to build or signal the early B-cell receptor, so B-cells get “stuck” at an early step and never mature. The condition is life-long, but regular antibody replacement greatly reduces infections and helps people live healthy, active lives. NCBI+1

In normal bone marrow, baby B-cells must assemble a “pre-B-cell receptor” and send signals that say “keep developing.” In autosomal agammaglobulinemia, faults in parts of this receptor or its wiring—like the μ heavy chain (IGHM), surrogate light chain (IGLL1), signaling modules (CD79A/CD79B), adaptor proteins (BLNK), transcription factor TCF3 (E2A), or the zinc transporter SLC39A7 (ZIP7)—block that checkpoint. Without those signals, B-cells do not progress and the blood ends up with extremely low or absent B-cells and very low IgG/IgA/IgM levels. That is why the hallmark is “no B-cells + no immunoglobulins,” and why treatment replaces the missing IgG from healthy donors. PMC+3Orpha+3Stem Cells Journal+3

Agammaglobulinemia, non-Bruton type is a group of rare, inherited immune system disorders where the body makes very few antibodies (also called “immunoglobulins”) because B cells fail to develop properly. Unlike classic (Bruton) agammaglobulinemia—which is X-linked and mainly affects boys—non-Bruton types are caused by changes in autosomal genes and can affect any sex. Because antibodies are low, people get frequent, often serious bacterial infections starting in infancy, typically after about six months of age when the mother’s antibodies wear off. Doctors usually find very low IgG, IgA, and IgM levels and very few or no circulating CD19+ B cells on blood tests. Genetic testing confirms the exact autosomal gene involved. GARD Information Center+2Rare Diseases+2

Other names

Doctors may also call this condition:

• Autosomal agammaglobulinemia

• Non-Bruton agammaglobulinemia

• Autosomal recessive agammaglobulinemia (ARA) or, less often, autosomal dominant agammaglobulinemia (ADA) depending on the gene and inheritance pattern
  All of these terms describe agammaglobulinemia due to autosomal gene defects rather than BTK on the X chromosome. GARD Information Center+1

Types

Non-Bruton agammaglobulinemia isn’t just one disease; it’s a family of gene-based disorders that block B-cell development at an early checkpoint. Below are well-described types and pathways:

1. IGHM (μ heavy chain) deficiency (AR) – failure to build the first B-cell receptor heavy chain. Nature

2. IGLL1 (λ5) deficiency (AR) – defective surrogate light chain in the pre-B-cell receptor. PMC

3. CD79A (Igα) defects (AR) – signal transduction problem at the pre-B-cell receptor. immunodeficiency

4. CD79B (Igβ) defects (AR) – partner signaling molecule to Igα also fails. Wiley Online Library

5. BLNK (B-cell linker) deficiency (AR; also called AGM4) – adapter protein problem downstream of the pre-B-cell receptor. Rare Diseases

6. PIK3R1 (p85α of PI3-kinase) variants (often AR; some AD) – signaling pathway defect that blocks B-cell maturation. Primary Immune

7. SLC39A7 (ZIP7) deficiency (AR; sometimes called AGM9) – zinc transporter defect that cripples B-cell signaling. PMC+1

8. LRRC8A variants (AD in reported families) – pre-B signaling/volume-regulated channel component implicated in human agammaglobulinemia. Wiley Online Library

9. TCF3 (E2A) variants (AD) – transcription factor defect needed for early B-cell commitment. Primary Immune

Notes: Multiple expert classifications (IUIS 2022 and 2024/2025 updates) group these under “defects in B-cell development and signaling,” and new genes continue to be added as research advances. PubMed+1

Causes

In non-Bruton agammaglobulinemia, “causes” are the specific gene defects or closely related mechanisms that stop B cells from forming. Each cause below is written as a short, plain paragraph.

1. IGHM gene variants (AR). When the μ heavy-chain gene is faulty, the “first draft” B-cell receptor cannot form, so immature B cells stop developing, and antibodies stay very low. Nature

2. IGLL1 (λ5) gene variants (AR). λ5 is part of the surrogate light chain that “tests” early B-cell receptors. Without it, B cells fail their checkpoint and vanish from the blood. PMC

3. CD79A (Igα) variants (AR). Igα carries signals from the surface receptor into the cell. A defect means signals don’t pass, so B cells cannot mature. immunodeficiency

4. CD79B (Igβ) variants (AR). Igβ partners with Igα. Faults here also block signaling and prevent B-cell development. Wiley Online Library

5. BLNK variants (AR). BLNK is an adapter protein that organizes downstream signals. Without BLNK, the pre-B receptor is “mute,” so B cells stall early. Rare Diseases

6. PIK3R1 variants (often AR). This gene encodes a PI3-kinase subunit that relays growth and survival signals; variants can produce profound B-cell failure and antibody deficiency. Primary Immune

7. SLC39A7 (ZIP7) variants (AR). ZIP7 moves zinc inside cells. Zinc is needed for many signaling enzymes; when ZIP7 is defective, B-cell signaling fades and B-cell numbers drop. PMC+1

8. LRRC8A variants (AD). This protein is part of a channel complex influencing cell volume and signaling. Pathogenic variants have been reported to cause agammaglobulinemia in humans. Wiley Online Library

9. TCF3 (E2A) variants (AD). TCF3 helps switch on early B-cell genes. Variants can prevent the B-cell program from starting, leading to no antibodies. Primary Immune

10. Pre-B-cell receptor assembly defects (mechanistic cause). Even without naming a single gene, any problem in assembling μ heavy chain + surrogate light chain + CD79A/B will block the pre-B checkpoint. Wiley Online Library

11. Pre-B-cell receptor signaling failure (mechanistic cause). If signals from the pre-B receptor cannot reach the nucleus (e.g., BLNK/PI3K pathway), B-cell maturation halts. Wiley Online Library

12. Autosomal recessive inheritance with consanguinity. When both parents carry the same rare variant, children have a higher chance of being affected; many autosomal cases are found in such settings. Primary Immune

13. De novo autosomal variants. Sometimes a new variant appears in a child for the first time, so there is no family history, yet the child still develops agammaglobulinemia. (General IEI principle.) PubMed

14. Compound heterozygosity. Having two different harmful variants in the same autosomal gene (one on each chromosome) can cause disease even if neither parent is affected. PubMed

15. Loss-of-function mutations. Truncating or splice-site changes that yield a nonfunctional protein often underlie the autosomal forms. Nature+1

16. Missense mutations disrupting critical domains. A single amino-acid change in a key signaling or receptor-assembly region can be enough to block B-cell development. PMC

17. Aberrant zinc homeostasis (ZIP7 pathway). Disrupted intracellular zinc signaling alters many enzymes needed for B-cell survival and receptor signaling. PMC

18. PI3K pathway imbalance. PI3K defects distort survival and metabolic cues in developing B cells; too little effective signaling leads to B-cell loss. Wiley Online Library

19. Adapter/scaffold failure (BLNK and partners). Without proper scaffolding, receptor signals don’t assemble correctly; the message to “grow and mature” never arrives. Rare Diseases

20. Unidentified autosomal genes (yet to be discovered). A fraction of patients have no mutation found with current testing; ongoing IUIS updates keep adding new genes. PubMed+1

Common symptoms and signs

1. Frequent ear infections (otitis media). Repeated bacterial ear infections are very common once maternal antibodies fade after six months of age. GARD Information Center

2. Chronic or recurrent sinusitis. Stuffy nose with pus-like drainage and facial pressure keeps returning because antibody defenses are weak. NCBI

3. Pneumonia and bronchitis. Chest infections occur often and can be severe, sometimes leading to long-term lung damage if untreated. NCBI

4. Skin infections and abscesses. Bacteria on the skin can cause boils or cellulitis more easily when antibodies are low. NCBI

5. Chronic diarrhea. Gut infections, including Giardia, are more common due to poor mucosal antibody protection. NCBI

6. Poor growth or “failure to thrive.” Ongoing infections and poor nutrient absorption can slow growth in infants and children. GARD Information Center

7. Meningitis or sepsis. Without antibodies, “invasive” bacterial infections like meningitis or bloodstream infections can occur. Rare Diseases

8. Small or absent tonsils and lymph nodes. Because B cells are missing, these tissues may look underdeveloped on exam. NCBI

9. Chronic cough or wheeze. Repeated chest infections can leave lasting airway irritation. NCBI

10. Sinopulmonary infections with encapsulated bacteria. Pathogens like Streptococcus pneumoniae and Haemophilus influenzae are classic offenders. NCBI

11. Conjunctivitis. Eye infections may be recurrent. NCBI

12. Arthritis or joint pain from infections. Bacteria can seed joints, causing pain and swelling. NCBI

13. Enteroviral complications (rare today with modern care). Historically, severe or persistent enteroviral infections were reported in agammaglobulinemia. UpToDate

14. Vaccine-associated problems with live vaccines. Live oral polio (no longer used in many countries) and some other live vaccines can cause infection in severe antibody deficiency; clinicians avoid these. UpToDate

15. Family history of early, recurrent infections. Especially in autosomal recessive forms from related parents or small communities. Primary Immune

Diagnostic tests

A) Physical examination

1. Head and neck exam. Doctors look for small/absent tonsils and chronic sinus tenderness or middle-ear fluid; these clues raise suspicion of B-cell failure. NCBI

2. Lymph node exam. Sparse or tiny lymph nodes suggest low B-cell development. NCBI

3. Chest exam. Crackles, wheeze, or signs of pneumonia/bronchiectasis point to recurrent chest infections. NCBI

4. Growth and nutrition check. Poor weight gain or short stature can reflect chronic infection and malabsorption. GARD Information Center

B) “Manual”/bedside tests and simple clinic procedures

5. Otoscopy and sinus transillumination. Simple in-office viewing helps document repeated ear/sinus infections that are typical in this condition. NCBI

6. Basic wound/skin swabs. When boils or cellulitis occur, swabbing guides targeted antibiotics and documents recurrent bacterial infection. NCBI

7. Peak flow or simple spirometry (screening). Office breathing tests can flag airway obstruction from repeated infections. (Formal lung function follows as needed.) NCBI

8. Vaccine review. Checking which vaccines were tolerated or ineffective can hint at antibody failure (e.g., poor response to protein/polysaccharide vaccines). UpToDate

C) Laboratory and pathological tests

9. Quantitative immunoglobulins (IgG, IgA, IgM). These are usually profoundly low in agammaglobulinemia. This is a key starting test. NCBI

10. Flow cytometry for lymphocyte subsets. Very low or absent CD19+ B cells with normal T cells strongly suggests agammaglobulinemia. NCBI

11. Specific antibody titers to vaccines (e.g., tetanus, pneumococcus). Poor or absent titers confirm functional antibody deficiency. UpToDate

12. Genetic testing panels/exome sequencing. Identifies autosomal variants (e.g., IGHM, IGLL1, CD79A/B, BLNK, PIK3R1, SLC39A7, LRRC8A, TCF3) and clarifies inheritance. Primary Immune+1

13. Newborn screening review (where available). While TREC-based screens focus on T cells, some programs capture severe B-cell defects indirectly; clinicians cross-check early results. (General IEI practice.) PubMed

14. Full blood count with differential. May be normal overall but shows very low absolute B cells on flow cytometry; neutropenia can occur with severe infection. NCBI

15. Stool antigen/PCR for Giardia. Looks for a common cause of chronic diarrhea in antibody deficiency. NCBI

16. Sputum cultures during infections. Help document typical encapsulated bacteria and tailor treatment; frequent positives support the diagnosis context. NCBI

17. Functional B-cell assays (specialized). Research/tertiary labs may test B-cell activation markers or phosphorylation responses to BCR stimulation to support a signaling defect. Wiley Online Library

18. Zinc-related investigations (for suspected ZIP7/SLC39A7). Some centers include functional studies that corroborate ZIP7-linked signaling failure. PMC

D) Electrodiagnostic / functional-signal readouts

19. Phospho-flow cytometry (p-BTK/p-AKT/p-ERK) after BCR stimulation. Although more specialized than routine care, these signal-readout tests show whether B-cell pathways fire correctly; in autosomal forms (e.g., BLNK/PI3K/ZIP7), signaling can be blunted. Wiley Online Library

20. Calcium-flux assays in B cells. Another lab-based functional test that tracks rapid electrical/ionic changes after receptor triggering; reduced flux supports a receptor/signaling defect. (Used in research/tertiary settings.) Wiley Online Library

E) Imaging tests

21. Chest X-ray. Shows pneumonias and, over time, structural changes from repeated infections. NCBI

22. High-resolution CT of the chest. Detects bronchiectasis (widened, damaged airways) in patients with long-standing lung infections. NCBI

23. Sinus CT. Documents chronic sinus disease when symptoms persist. NCBI

24. Ultrasound of lymphoid tissues (as needed). May show small tonsillar/lymph node tissue consistent with B-cell absence, complementing the clinical exam. NCBI

Non-pharmacological treatment pillars

1) Lifelong education & early infection action plans.
Families learn to spot infection early, collect cultures when possible, and start antibiotics promptly. This reduces lung damage (bronchiectasis) and hospital stays. A simple written plan (fever thresholds, when to call, when to come in) is recommended for primary immunodeficiency. Rare Diseases

2) Immunization strategy for the household (herd protection).
People with agammaglobulinemia shouldn’t get live vaccines, but their family and close contacts should be fully vaccinated (using inactivated vaccines) to build a “ring” of protection. This includes flu and COVID-19 vaccines for contacts; for the patient, inactivated vaccines are generally safe but often ineffective while on Ig therapy. CDC+1

3) Avoid live vaccines in the patient; use inactivated where appropriate.
Live oral polio, MMR, varicella, live influenza (nasal spray), yellow fever, BCG, and live typhoid are generally contraindicated in major antibody deficiencies; inactivated vaccines may be given but responses can be blunted by ongoing Ig therapy. CDC+1

4) Respiratory hygiene & airway clearance.
Daily saline nasal rinses, prompt sinus care, and, when needed, chest physiotherapy and airway clearance cut down mucus stasis and bacterial growth in chronic sinusitis or early bronchiectasis common to humoral immunodeficiencies. (These measures complement, not replace, Ig and antibiotics.) NCBI

5) Infection-risk reduction at home/school.
Hand hygiene, safe food/water practices, avoiding sick contacts during outbreaks, and rapid evaluation of fevers are standard common-sense steps endorsed for patients with primary immunodeficiencies to prevent severe infections. Rare Diseases

6) Dental and ENT maintenance.
Regular dental care and ENT follow-up help prevent chronic otitis/sinus disease and related complications, which are common in antibody deficiency without Ig. NCBI

7) Travel and vaccine planning.
Before travel, review destination vaccine needs and alternatives to live vaccines (e.g., inactivated polio schedules), and plan to carry antibiotics and documentation of the diagnosis and Ig schedule. Live yellow fever vaccine is generally avoided; individualized specialist advice is essential. CDC

8) Pulmonary monitoring.
Baseline and periodic lung evaluation (exam, spirometry ± imaging when indicated) helps catch bronchiectasis early in patients with repeated chest infections, a known risk in untreated or undertreated antibody deficiencies. NCBI

---

Drug treatments

1) Immunoglobulin replacement—foundation therapy (IVIG).
What it is & why: Purified IgG from donors replaces the antibodies the body can’t make, preventing severe infections and reducing hospitalizations. Dose: common starting dose 400–600 mg/kg IV every 3–4 weeks, then adjust to keep IgG trough high and infections low. Mechanism: passive humoral immunity—neutralizes pathogens and opsonizes bacteria. Side effects: infusion reactions (headache, chills), rare thrombosis or aseptic meningitis—mitigated by rate control and hydration. PMC+1

2) Immunoglobulin replacement—subcutaneous (SCIG).
What & why: Weekly or bi-weekly SCIG (home-based) gives steadier IgG with fewer systemic reactions and high patient satisfaction. Typical dose: ~100–150 mg/kg/week (or equivalent to prior IVIG monthly total), split among sites; titrate to clinical control. Mechanism/SEs: same as IVIG; local site swelling/itching common and usually mild. Allergy Australia+1

3) Brand examples (FDA-recognized Ig products).
Common US products include Hizentra® (SCIG 20%), Gammagard Liquid® (IVIG 10%), Cuvitru® (SC/IV 20%), Gamunex-C® (IV/SC 10%), Xembify® (SC 20%), Cutaquig® (SC 16.5%)—all used according to their FDA-cleared labels or biologics licenses. Choice depends on access, route preference, and tolerance. FDA Access Data+2FDA Access Data+2

4) Targeted, prompt antibiotics for acute infections.
Because encapsulated bacteria (e.g., Streptococcus pneumoniae, Haemophilus influenzae) are common pathogens in antibody deficiencies, clinicians treat early and sufficiently long, guided by cultures when possible (e.g., amoxicillin-clavulanate or macrolides for sinusitis/bronchitis; broader agents for pneumonia as needed). NCBI

5) Prophylactic antibiotics in selected cases.
If significant infections continue despite optimized Ig therapy, some clinicians add prophylactic azithromycin or other agents to reduce sinus/chest infections—always balanced against resistance risks and side effects. NCBI

6) Vaccines for contacts and inactivated vaccines for the patient.
Although vaccine responses can be poor on Ig therapy, annual inactivated influenza for the patient and full vaccination for close contacts lower exposure and severity; live vaccines are avoided in the patient. Primary Immune+1

7) Antivirals or antifungals (case-by-case).
These are not routine but may be needed for proven viral or fungal infections (e.g., influenza antivirals during documented flu, or antifungals for culture-proven disease) because humoral defects mainly predispose to bacterial infections. NCBI

8) Curative approaches (selected gene defects)—HSCT consideration.
For some rare autosomal forms with severe, refractory disease, hematopoietic stem cell transplantation may be considered in specialized centers; it can reconstitute B-cell development when a stable graft is achieved. Decisions are individualized given risks and the effectiveness of lifelong Ig. NCBI

---

Dietary & molecular supplements

1) General nutrition to support healing.
A balanced diet with adequate protein, fruits/vegetables, whole grains, and healthy fats supports tissue repair during infections and overall energy—this complements, but does not replace, Ig therapy and antibiotics. (No supplement can “cure” agammaglobulinemia.) Rare Diseases

2) Vitamin D (when deficient).
Correcting vitamin D deficiency supports general immune health and bone health, especially important for children. Dosing is individualized based on blood levels; avoid excessive dosing. This is supportive care, not a treatment for the B-cell defect. Rare Diseases

3) Zinc—use caution and individualize.
Zinc is essential to immunity; intriguingly, ZIP7 (SLC39A7) mutations cause one autosomal agammaglobulinemia subtype by disturbing intracellular zinc signaling. That does not mean high-dose oral zinc fixes the genetic problem; supplementation should only correct true deficiency. PMC+1

4) Probiotics—avoid live organisms unless your specialist approves.
Because live microbes can cause infection in immunodeficiency, live probiotic products are usually avoided. Dietary fermented foods may also carry risk. Discuss gut health strategies with your immunology team. CDC

---

Immunity-booster / regenerative / stem-cell–related

A) FDA-recognized immune globulin products (biologics).
These are the cornerstone “immune replacement” products for primary humoral immunodeficiency: Hizentra®, Gammagard Liquid®, Cuvitru®, Gamunex-C®, Xembify®, Cutaquig®. Labels/clearances confirm their use for PI; dosing and administration follow product prescribing information and infusion-device compatibility documents. FDA Access Data+2FDA Access Data+2

B) Infusion systems cleared for SCIG administration.
Multiple 510(k) clearances explicitly list compatibility with Ig products (e.g., EMED SCIg60/VersaPump; KORU Freedom systems), supporting safe home SCIG delivery when used per labeling. (These are devices, not drugs, but they enable regenerative day-to-day immune replacement.) FDA Access Data+2FDA Access Data+2

Note: There is no FDA-approved “stem-cell drug” for agammaglobulinemia. Curative HSCT is a procedure, not a drug, and is undertaken in specialized centers after risk–benefit evaluation. NCBI

---

Procedures / surgeries

1) Central venous access (ports) for IVIG (when SCIG not feasible).
Some patients who cannot tolerate veins or prefer monthly IVIG may need a port. It should be balanced against line-infection risks; many patients can avoid ports by switching to home SCIG. Allergy Australia

2) Tympanostomy tubes / sinus surgery for chronic ENT disease.
In children with recurrent otitis media or chronic sinusitis despite optimal medical care, procedures can reduce pain, effusions, and infection burden, complementing Ig therapy—not replacing it. NCBI

3) Hematopoietic stem cell transplantation (HSCT) for selected genes.
Considered in severe, refractory autosomal forms; may restore B-cell development. Requires transplant-center evaluation; not routine because many patients do well on Ig. NCBI

---

Practical prevention tips

1. Keep all Ig doses on schedule; don’t skip. Allergy Australia

2. Treat fevers and infections early; don’t “watch and wait.” NCBI

3. No live vaccines for the patient; ensure contacts are fully vaccinated. CDC+1

4. Yearly inactivated flu for the patient and all household members. CDC

5. Good hand hygiene and safe food/water practices daily. Rare Diseases

6. Keep a supply of rescue antibiotics if your clinician advises it. NCBI

7. Regular dental/ENT check-ups. NCBI

8. Plan ahead for travel; avoid destinations requiring live vaccines. CDC

9. Monitor lungs if you have frequent chest infections. NCBI

10. Maintain good nutrition and rest during illness. Rare Diseases

---

When to see a doctor urgently

See a clinician now for fever ≥38.5 °C, fast or labored breathing, chest pain, severe ear/sinus pain, vomiting/diarrhea with dehydration, persistent cough, new rash with fever, severe headache/neck stiffness, or any infection not improving after 48–72 hours of antibiotics. People with agammaglobulinemia can worsen quickly without antibodies; early evaluation prevents complications. NCBI

---

What to eat & what to avoid

Eat: Regular balanced meals rich in protein (eggs, fish, legumes), fruits/vegetables for micronutrients, whole grains for energy, and healthy fats. Hydrate well—especially during infections—to thin mucus and support recovery. Correct specific deficiencies (e.g., vitamin D) under medical guidance. Rare Diseases

Avoid/Use caution: Raw or undercooked meats/eggs/fish; unpasteurized dairy; untreated water; live probiotic products unless your specialist approves; and any live-attenuated vaccine given directly to the patient. CDC

---

FAQs

1) Is autosomal agammaglobulinemia the same as Bruton disease?
No. Bruton disease is X-linked (BTK gene). “Non-Bruton” forms are autosomal and caused by other genes that block early B-cell development. Both lead to absent B-cells and very low immunoglobulins. NCBI+1

2) When do symptoms start?
Often after 6–9 months of age when maternal antibodies fade, leading to repeated ear, sinus, lung, and gut infections. NCBI

3) How is it diagnosed?
Very low immunoglobulins, absent/very low B-cells (CD19+), small tonsils/lymph nodes, and confirmatory genetic testing showing a non-BTK gene. NCBI+1

4) What is the main treatment?
Lifelong Ig replacement (IVIG or SCIG) with individualized dosing to keep IgG troughs high and infections low. PMC+1

5) Can I get vaccinated?
Avoid live vaccines; inactivated vaccines are generally safe but may not work well on Ig. Household members should be fully vaccinated to protect you. CDC+1

6) Will antibiotics still be needed?
Yes. Even with Ig, prompt and sometimes preventive antibiotics are used to control bacterial infections. NCBI

7) Is there a cure?
No simple drug “cure.” In selected severe autosomal cases, HSCT may restore B-cell development; this is specialized and not routine. NCBI

8) What about zinc or other supplements?
Only correct true deficiencies. ZIP7 (SLC39A7) agammaglobulinemia is a zinc-transport signaling problem inside cells; taking extra zinc by mouth does not fix the gene defect. PMC+1

9) Is home therapy possible?
Yes. Many patients switch to SCIG at home, often with compatible, FDA-cleared infusion systems, for steady IgG levels and independence. Allergy Australia+1

10) What is the long-term outlook?
With regular Ig therapy, early infection management, and vaccine planning for contacts, most people can lead active lives and avoid serious complications. Primary Immune

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 30, 2025.